143 related articles for article (PubMed ID: 33675908)
1. TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.
Gandini S; Zanna I; De Angelis S; Palli D; Raimondi S; Ribero S; Masala G; Suppa M; Bellerba F; Corso F; Nezi L; Nagore E; Caini S
Crit Rev Oncol Hematol; 2021 Apr; 160():103288. PubMed ID: 33675908
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
3. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis.
Zanna I; Caini S; Raimondi S; Saieva C; Masala G; Massi D; Cocorocchio E; Queirolo P; Stanganelli I; Gandini S
Mol Carcinog; 2021 Mar; 60(3):167-171. PubMed ID: 33444485
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
Hugdahl E; Kalvenes MB; Mannelqvist M; Ladstein RG; Akslen LA
Br J Cancer; 2018 Jan; 118(1):98-105. PubMed ID: 29123258
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
7. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
8. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
9. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
[TBL] [Abstract][Full Text] [Related]
10. Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.
Wang X; Li X; Xu F; Zhang Y; Liu H; Tao Y
Mol Neurobiol; 2016 May; 53(4):2726-32. PubMed ID: 26351078
[TBL] [Abstract][Full Text] [Related]
11.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
12. TERT promoter mutations in melanoma survival.
Nagore E; Heidenreich B; Rachakonda S; Garcia-Casado Z; Requena C; Soriano V; Frank C; Traves V; Quecedo E; Sanjuan-Gimenez J; Hemminki K; Landi MT; Kumar R
Int J Cancer; 2016 Jul; 139(1):75-84. PubMed ID: 26875008
[TBL] [Abstract][Full Text] [Related]
13. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
14. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma.
Cho WC; Wang WL; Milton DR; Ingram DR; Nagarajan P; Curry JL; Ivan D; Lazar AJ; Hwu WJ; Prieto VG; Torres-Cabala CA; Aung PP
Arch Pathol Lab Med; 2021 Jul; 145(7):842-850. PubMed ID: 33053175
[TBL] [Abstract][Full Text] [Related]
15. Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma.
Cho WC; Li W; Gu J; Wang WL; Ning J; Sfamenos S; Gill P; Nagarajan P; Curry JL; Lazar AJ; Prieto VG; Torres-Cabala CA; Aung PP
J Cutan Pathol; 2023 Sep; 50(9):845-851. PubMed ID: 37400233
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
17. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
[TBL] [Abstract][Full Text] [Related]
18. High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.
Ekedahl H; Lauss M; Olsson H; Griewank KG; Schadendorf D; Ingvar C; Jönsson G
Pigment Cell Melanoma Res; 2016 Sep; 29(5):598-600. PubMed ID: 27301352
[No Abstract] [Full Text] [Related]
19. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
Lade-Keller J; Yuusufi S; Riber-Hansen R; Steiniche T; Stougaard M
Melanoma Res; 2018 Oct; 28(5):398-409. PubMed ID: 29570169
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]